Subject terms
NSCLC
MUTANT, NON-SMALL CELL LUNG CANCER, NSCLC
Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (Afatinib is a second-generation EGFR tyrosine kinase inhibitor recommended as the first-line treatment for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). Here the authors report the results of a phase II clinical trial of neoadjuvant afatinib for stage III EGFR mutant NSCLC.